Upon finding that androgen deprivation therapy for prostate cancer is linked to a slightly increased risk of developing diabetes and cardiovascular disease, the US Food and Drug Administration has required such medications to carry a warning label for the risks, and advised clinicians to monitor patients receiving the therapy for these conditions.

Full article